News

Senores Pharmaceuticals Limited announced several key corporate decisions, including the appointment of Dr. Viranchi Arvindbhai Shah as a Director and Ms. Shivali Shah as Company Secretary, with no related party concerns. The board also approved the Senores Pharmaceuticals Employee Stock Option Scheme 2026 (ESOS 2026), granting 4,72,000 options, representing 1% of fully diluted equity, to eligible employees with vesting occurring over 1 to 4 years. Furthermore, the company plans to establish wholly-owned subsidiaries in Mexico and Canada to expand its presence in those pharmaceutical markets, requiring cash investment and adherence to local regulatory approvals. The Canadian subsidiary will be at least 51% owned by Senores Pharmaceuticals, either directly or through its Mexican subsidiary.

Net profit of Senores Pharmaceuticals rose 55.70% to Rs 30.72 crore in the quarter ended June 2026 as against Rs 19.73 crore during the previous quarter ended June 2025. Sales rose 38.30% to Rs 180.21 crore in the quarter ended June 2026 as against Rs 130.30 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales180.21130.30 38 OPM %29.8326.22 - PBDT49.4032.48 52 PBT39.4626.49 49 NP30.7219.73 56 Powered by Capital Market - Live News

Senores Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 27 July 2026.

Net profit of Senores Pharmaceuticals rose 77.29% to Rs 31.61 crore in the quarter ended March 2026 as against Rs 17.83 crore during the previous quarter ended March 2025. Sales rose 53.39% to Rs 175.19 crore in the quarter ended March 2026 as against Rs 114.21 crore during the previous quarter ended March 2025.For the full year,net profit rose 96.99% to Rs 115.36 crore in the year ended March 2026 as against Rs 58.56 crore during the previous year ended March 2025. Sales rose 58.85% to Rs 632.63 crore in the year ended March 2026 as against Rs 398.25 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales175.19114.21 53 632.63398.25 59 OPM %27.1117.02 -26.6122.52 - PBDT56.7025.91 119 190.3587.41 118 PBT47.4020.68 129 159.1070.57 125 NP31.6117.83 77 115.3658.56 97 Powered by Capital Market - Live News

Senores Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 May 2026.